drugset / Trial / NCT06747312
Effect of Belimumab on Antibody Titers in Primary APS Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belimumab | Monoclonal antibody | 10 mg/kg | Intravenous |